New Clinical Trial For Metastatic Prostate Cancer

MEVPRO-1 is a Phase 3 randomized, open-label clinical trial to evaluate an investigational medicine taken orally by tablets called mevrometostat for men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed after treatment with abiraterone acetate (Zytiga®).

MEVPRO-1 will investigate whether mevrometostat in combination with enzalutamide is superior to either enzalutamide or docetaxel in prolonging radiographic progression-free survival in the mCRPC setting.

Investigational mevrometostat has the potential to be the first-in-class EZH2 inhibitor for prostate cancer.

MEVPRO-1 is enrolling adult men (18+) who:

• Have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features
• Have evidence of disease progression on or after treatment with at least 12 weeks of abiraterone acetate in the metastatic castration-sensitive prostate (mCSPC) cancer or first-line mCRPC setting
• Have metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan

Learn more